The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is
regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of …

ABSTRACT Introduction Erythropoiesis-stimulating agents (ESAs) are the standard of
treatment for anemia in chronic kidney disease. Hypoxia-inducible factor prolyl hydroxylase …

Anemia plays an important role in chronic kidney disease (CKD) progression because it
worsens the quality of life and increases the risk of cardiovascular complications in CKD …

The objective was to provide a comprehensive summary of existing evidence on the efficacy
and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) for the …

Purpose To review current evidence on the efficacy and safety outcomes of HIF-PHIs in
chronic kidney disease (CKD) populations with an emphasize on the safety profile. Methods …

Objective We retrospectively compared the dose, cost, and safety of vadadustat and
daprodustat for the treatment of renal anemia in patients with chronic kidney diseases who …

Cancer remains one of the most formidable challenges in modern medicine, due to its
complex and dynamic nature, which demands innovative therapeutic approaches. One …

Background Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP)-
glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of …

Anaemia is a common complication of chronic kidney disease (CKD) and is associated with
poor long-term outcomes and quality of life. The use of supplemental iron, erythropoiesis …

Anemia is a major complication of chronic kidney disease (CKD). Its prevalence increases
with advancing age and progression of kidney disease. The main cause of anemia linked to …